The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.
Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.
The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.
Genomics England will use the product to aid scientists and clinicians in 13 National Health Service Genomic Medical Centres with clinical reporting and interpretation.
Researchers reported on the impact sequencing projects have already had on participants, as well as the challenges, particularly in data interpretation and storage.
Proponents believe the Million European Genomes Alliance will spur research, stimulate the life sciences economy, and ultimately improve clinical care.
